(NASDAQ: ENGN) Engene Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Engene Holdings's revenue in 2025 is $0.On average, 6 Wall Street analysts forecast ENGN's revenue for 2027 to be $1,915,391,304, with the lowest ENGN revenue forecast at $536,489,760, and the highest ENGN revenue forecast at $4,446,466,037. On average, 5 Wall Street analysts forecast ENGN's revenue for 2028 to be $6,045,645,772, with the lowest ENGN revenue forecast at $3,991,422,385, and the highest ENGN revenue forecast at $8,380,092,913.
In 2029, ENGN is forecast to generate $11,815,879,815 in revenue, with the lowest revenue forecast at $9,990,074,111 and the highest revenue forecast at $14,318,338,349.